TR200200774T2 - Aşılar. - Google Patents

Aşılar.

Info

Publication number
TR200200774T2
TR200200774T2 TR2002/00774T TR200200774T TR200200774T2 TR 200200774 T2 TR200200774 T2 TR 200200774T2 TR 2002/00774 T TR2002/00774 T TR 2002/00774T TR 200200774 T TR200200774 T TR 200200774T TR 200200774 T2 TR200200774 T2 TR 200200774T2
Authority
TR
Turkey
Prior art keywords
adjuvants
production
aces
adjuvant system
vaccines
Prior art date
Application number
TR2002/00774T
Other languages
English (en)
Turkish (tr)
Inventor
Friede Martin
Hermand Phlippe
Henerickx Veronique
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9922703.5A external-priority patent/GB9922703D0/en
Priority claimed from GB0016685A external-priority patent/GB0016685D0/en
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of TR200200774T2 publication Critical patent/TR200200774T2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
TR2002/00774T 1999-09-24 2000-09-22 Aşılar. TR200200774T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922703.5A GB9922703D0 (en) 1999-09-24 1999-09-24 Vaccine
GB0016685A GB0016685D0 (en) 2000-07-06 2000-07-06 Novel compounds

Publications (1)

Publication Number Publication Date
TR200200774T2 true TR200200774T2 (tr) 2002-08-21

Family

ID=26244613

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00774T TR200200774T2 (tr) 1999-09-24 2000-09-22 Aşılar.

Country Status (17)

Country Link
EP (1) EP1221971A2 (fr)
JP (1) JP2003509473A (fr)
KR (1) KR20020038770A (fr)
CN (1) CN1391483A (fr)
AU (1) AU765824B2 (fr)
BR (1) BR0014282A (fr)
CA (1) CA2383413A1 (fr)
CO (1) CO5200837A1 (fr)
CZ (1) CZ20021043A3 (fr)
HK (1) HK1049106A1 (fr)
HU (1) HUP0202885A3 (fr)
IL (1) IL148672A0 (fr)
MX (1) MXPA02003067A (fr)
NO (1) NO20021433L (fr)
PL (1) PL355163A1 (fr)
TR (1) TR200200774T2 (fr)
WO (1) WO2001021207A2 (fr)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909323B1 (fr) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Bacterioferritine de helicobacter pilori
CA2881568C (fr) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Acides nucleiques et proteines derives des groupes de streptocoques a et b
AU2002227365A1 (en) 2000-12-07 2002-06-18 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CA2476626A1 (fr) 2002-02-20 2003-08-28 Chiron Corporation Microparticules comprenant des molecules adsorbees qui contiennent polypeptides
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
SI2351579T1 (sl) 2002-10-11 2017-05-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004060396A2 (fr) 2002-12-27 2004-07-22 Chiron Corporation Immunogenes contenant des compositions de phospholipide
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
CA2522379C (fr) 2003-04-10 2012-10-23 Chiron Corporation Le coronavirus du syndrome respiratoire aigu grave
US9107831B2 (en) 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
ATE506963T1 (de) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2005107797A1 (fr) 2004-03-09 2005-11-17 Chiron Corporation Vaccins antigrippaux
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
PL1740217T3 (pl) 2004-04-30 2012-03-30 Novartis Ag Szczepienie koniugatem meningokokowym
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
CA2567446C (fr) 2004-05-21 2018-01-02 Chiron Corporation Vecteurs d'alphavirus pour vaccins contre pathogenes respiratoires
EP1765313A2 (fr) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Composes utilises pour l'immunopotentialisation
WO2006078318A2 (fr) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Compositions immunogenes pour bacteries a gram positif telles que streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
PT2682126T (pt) 2005-01-27 2017-02-28 Children`S Hospital & Res Center At Oakland Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
HUE030881T2 (en) 2005-02-18 2017-06-28 Glaxosmithkline Biologicals Sa Meningitis / sepsis-associated escherichia coli proteins and nucleic acids
WO2007015441A1 (fr) 2005-08-01 2007-02-08 Hisamitsu Pharmaceutical Co., Inc. Adjuvant ou préparation pharmaceutique pour administration transdermique ou transmucosale
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514838A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 細胞培養物において増殖されたインフルエンザウイルスから調製された非ビリオン抗原を含むアジュバントワクチン
WO2007052057A2 (fr) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Voies d'administration pour sensibilisation/stimulation par des vaccins contre la grippe
EP2360175B1 (fr) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Particules de type virus (vlps) de norovirus et de sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
DK2478916T3 (da) 2006-01-27 2020-06-15 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
US8535683B2 (en) 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
CA2646349A1 (fr) * 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Stockage de vaccins antigrippaux sans refrigeration
WO2007126825A2 (fr) 2006-03-31 2007-11-08 Novartis Ag Immunisation mucosale et parentérale combinée contre le vih
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
ES2694805T7 (es) 2006-09-11 2021-10-21 Seqirus Uk Ltd Fabricación de vacunas contra virus de la gripe sin usar huevos
SG177141A1 (en) 2006-12-06 2012-01-30 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2123296B1 (fr) * 2007-01-31 2019-05-22 Hisamitsu Pharmaceutical Co., Inc. Adjuvant pour administration transdermique ou transmucosale et preparation pharmaceutique le contenant
EP2185191B1 (fr) 2007-06-27 2012-09-12 Novartis AG Vaccins antigrippaux à faible teneur en additifs
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8815253B2 (en) 2007-12-07 2014-08-26 Novartis Ag Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ601543A (en) 2007-12-21 2013-03-28 Novartis Ag Mutant forms of streptolysin o
EP2886551A3 (fr) 2008-02-21 2015-09-23 Novartis AG Polypeptides fHbp méningococciques
US9511131B2 (en) 2008-03-10 2016-12-06 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
NZ592977A (en) 2008-12-09 2013-01-25 Pfizer Vaccines Llc IgE CH3 PEPTIDE VACCINE
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
NZ594029A (en) 2009-01-12 2014-01-31 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
JP5642712B2 (ja) 2009-02-10 2014-12-17 ノバルティス アーゲー 少ない量のスクアレンを含むインフルエンザワクチン
RU2011140508A (ru) 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
CN109248313B (zh) 2009-04-14 2023-01-17 葛兰素史密丝克莱恩生物有限公司 用于免疫接种以抵御金黄色葡萄球菌的组合物
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
EP2442826B1 (fr) 2009-06-15 2015-07-08 National University of Singapore Vaccin contre l'influenza, composition, et procedes d'utilisation
JP2012532600A (ja) 2009-07-07 2012-12-20 ノバルティス アーゲー 保存された大腸菌免疫原
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
PT2464658E (pt) 2009-07-16 2015-01-14 Novartis Ag Imunogénios de escherichia coli desintoxicados
NZ618391A (en) 2009-07-30 2015-07-31 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
EP2470204B1 (fr) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Polypeptides hybrides contenant des séquences fhbp à méningocoques
KR101660578B1 (ko) 2009-09-03 2016-09-27 화이자 백신스 엘엘씨 Pcsk9 백신
CA2779798C (fr) 2009-09-30 2019-03-19 Novartis Ag Conjugaison de polysaccharides capsulaires de staphylococcus aureus de type 5 et de type 8
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011077309A2 (fr) 2009-12-22 2011-06-30 Pfizer Vaccines Llc Compositions de vaccin
EP2519265B1 (fr) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
EP2552942B1 (fr) 2010-03-30 2017-12-27 Children's Hospital & Research Center at Oakland Protéines de liaison du facteur h (fhbp) avec des propriétés altérées et leurs procédés d'utilisation
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
CA2796314A1 (fr) 2010-04-13 2011-10-20 Novartis Ag Compositions de benzonapthyridine et leurs utilisations
EP2575868A1 (fr) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Vaccin peptidique ige ch3
WO2011154863A1 (fr) 2010-06-07 2011-12-15 Pfizer Inc. Peptides her-2 et vaccins
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US20130171185A1 (en) 2010-07-06 2013-07-04 Ethan Settembre Norovirus derived immunogenic compositions and methods
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
PT2667892T (pt) 2011-01-26 2019-06-07 Glaxosmithkline Biologicals Sa Regime de imunização contra o vsr
WO2012131504A1 (fr) 2011-03-02 2012-10-04 Pfizer Inc. Vaccin à base de pcsk9
PT2707385T (pt) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Antigénios de f de rsv pré-fusão
JP2014520807A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
EP2729165B1 (fr) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Compositions de combinaisons immunogènes et utilisations de celles-ci
US10030052B2 (en) 2011-07-25 2018-07-24 Glaxosmithkline Biologicals Sa Parvovirus Vp1 unique region polypeptides and compositions thereof
EP2659906A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
EP3563865A3 (fr) 2012-05-04 2019-12-04 Pfizer Inc Régimes immunothérapeutiques basés sur des antigènes associés à la prostate et un vaccin
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
WO2014005958A1 (fr) 2012-07-06 2014-01-09 Novartis Ag Compositions immunogéniques et leurs utilisations
EA201590427A1 (ru) 2012-10-02 2015-09-30 Глаксосмитклайн Байолоджикалс С.А. Нелинейные сахаридные конъюгаты
RU2015106791A (ru) 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са Иммуногенные композиции
AU2013351182C1 (en) 2012-11-30 2018-11-08 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CA2909586C (fr) 2013-05-15 2021-08-31 The Governors Of The University Of Alberta Vaccins contre le vhc e1e2 et procedes d'utilisation desdits vaccins
WO2015064710A1 (fr) 2013-10-31 2015-05-07 久光製薬株式会社 Composition adjuvante, préparation adjuvante la contenant et kit
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2015208821B2 (en) 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (fr) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Vaccin à base de pcsk9 et méthodes d'utilisation dudit vaccin
CA3212723A1 (fr) 2014-07-23 2016-01-28 Peter T. Beernink Variants de proteines de liaison au facteur h et procedes d'utilisation de ceux-ci
FI3244917T3 (fi) 2015-01-15 2023-05-25 Pfizer Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
WO2017005851A1 (fr) 2015-07-07 2017-01-12 Affiris Ag Vaccins pour le traitement et la prévention de maladies médiées par ige
TWI756893B (zh) 2015-07-21 2022-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
CA3005524C (fr) 2015-11-20 2023-10-10 Pfizer Inc. Compositions immunogenes destinees a etre utilisees dans des vaccins pneumococciques
CA2954892A1 (fr) 2016-01-19 2017-07-19 Pfizer Inc. Immunogenes derives d'antigenes associes a une tumeur ou des modules d'acide nucleique codant les immunogenes
DK3570879T3 (da) 2017-01-20 2022-04-11 Pfizer Immunogene sammensætninger til anvendelse i pneumokokvacciner
WO2019173438A1 (fr) 2018-03-06 2019-09-12 Stc. Unm Compositions et méthodes pour faire baisser les triglycérides sériques
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
JP2022528158A (ja) 2019-04-10 2022-06-08 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物、それを含むキットおよびその使用
IL292494A (en) 2019-11-01 2022-06-01 Pfizer Preparations of Escherichia coli and their methods
AU2021224078B2 (en) 2020-02-21 2024-01-18 Pfizer Inc. Purification of saccharides
EP4107170A2 (fr) 2020-02-23 2022-12-28 Pfizer Inc. Escherichia coli compositions d'et méthodes associées
TW202227467A (zh) 2020-10-27 2022-07-16 美商輝瑞大藥廠 大腸桿菌組合物及其方法
KR20230097160A (ko) 2020-11-04 2023-06-30 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
JP2023549736A (ja) 2020-11-10 2023-11-29 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
TWI750929B (zh) * 2020-12-02 2021-12-21 林建宏 氣霧免疫用之溫敏型佐劑及其製作方法
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (fr) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes imitant la pcsk9 guidés par des anticorps et ne présentant pas de chevauchement de séquence de 9 résidus avec des protéines humaines
MX2023009728A (es) 2021-02-19 2023-08-30 Sanofi Pasteur Inc Vacuna recombinante meningococica b.
WO2022234483A1 (fr) 2021-05-04 2022-11-10 King Abdullah University Of Science And Technology Compositions immuogéniques de protéine n mutante de sars-cov-2 et gène et procédés d'utilisation associés
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
PE20240090A1 (es) 2021-05-28 2024-01-16 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
WO2023079528A1 (fr) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions appropriées pour une utilisation dans un procédé pour déclencher une immunité protectrice croisée contre des coronavirus
WO2023079529A1 (fr) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions d'immunisation de rappel de protéine de refocalisation et leurs méthodes d'utilisation
CA3237496A1 (fr) 2021-11-18 2023-05-25 Matrivax, Inc. Compositions de proteines de fusion immunogenes et leurs procedes d'utilisation
WO2023135515A1 (fr) 2022-01-13 2023-07-20 Pfizer Inc. Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2023161817A1 (fr) 2022-02-25 2023-08-31 Pfizer Inc. Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
WO2023218322A1 (fr) 2022-05-11 2023-11-16 Pfizer Inc. Procédé de production de formulations de vaccin avec des conservateurs
WO2024018061A1 (fr) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Utilisation de souches de bordetella pour le traitement de la bronchopneumopathie chronique obstructive

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
NL8403195A (nl) * 1984-10-19 1986-05-16 Nederlanden Staat Immunogene complexen en vaccins die deze bevatten.
CA1291036C (fr) * 1986-04-23 1991-10-22 Edwin I. Stoltz Administration de medicaments par voie nasale
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals

Also Published As

Publication number Publication date
IL148672A0 (en) 2002-09-12
CZ20021043A3 (cs) 2002-08-14
HK1049106A1 (zh) 2003-05-02
CA2383413A1 (fr) 2001-03-29
CO5200837A1 (es) 2002-09-27
WO2001021207A2 (fr) 2001-03-29
AU7907000A (en) 2001-04-24
NO20021433D0 (no) 2002-03-21
AU765824B2 (en) 2003-10-02
JP2003509473A (ja) 2003-03-11
WO2001021207A3 (fr) 2001-09-27
HUP0202885A2 (hu) 2002-12-28
NO20021433L (no) 2002-05-21
BR0014282A (pt) 2002-05-21
PL355163A1 (en) 2004-04-05
HUP0202885A3 (en) 2004-07-28
CN1391483A (zh) 2003-01-15
MXPA02003067A (es) 2002-09-30
KR20020038770A (ko) 2002-05-23
EP1221971A2 (fr) 2002-07-17

Similar Documents

Publication Publication Date Title
TR200200774T2 (tr) Aşılar.
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
HUP0203817A2 (hu) Polioxietilén-alkil-étert vagy -észtert és legalább egy nemionos felületaktív anyagot tartalmazó adjuváns
TR200102739T2 (tr) Aşı
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
WO2001034801A3 (fr) Vaccins contenant de la gelatine recombinante
DE602004020189D1 (de) Adjuvante influenza-vakzine
DK1326633T3 (da) Sammensætning omfattende immunogene mikropartikler
ATE305030T1 (de) Veränderter stamm des modifizierten vaccinia- virus ankara (mva)
NO20015073L (no) Vaksiner
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
GB0123580D0 (en) Vaccine
AU2001291687A1 (en) Polyammonium-polysiloxane compounds, methods for the production and use thereof
HUP0301180A2 (hu) Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
AR025750A1 (es) Vacunas
CY1105684T1 (el) Ανοσοενισχυτικα εμβολιων
ATE263189T1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
DK1242108T3 (da) Optimerede minigener og peptider kodet derved
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
DE60136360D1 (de) Antigen aus streptococcus pyogenes
DE60115051D1 (de) Immunologische adjuvans verbindungen
MXPA05004081A (es) Metodo para el tratamiento de fibras, hilos de alfombras y alfombras, para aumentar su repelencia.
DK1290160T3 (da) Humane Pellino-polypeptider
EA200301151A1 (ru) Вакцина против натуральной оспы